Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
Liedberg F, Chebil G, Månsson W.
Expert Rev Anticancer Ther. 2007 Mar;7(3):383-90. doi: 10.1586/14737140.7.3.383.
Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature.
Liu L, Sun FZ, Zhang PY, Xiao Y, Yue X, Wang DM, Wang Q.
Aging Male. 2023 Dec;26(1):2252102. doi: 10.1080/13685538.2023.2252102.
The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y, Zhang G, Hu C, Luo W, Jiang H, Liu S, Yang H.
BMC Urol. 2022 Nov 30;22(1):196. doi: 10.1186/s12894-022-01141-1.
[Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
Huguet J.
Actas Urol Esp. 2012 Oct;36(9):545-53. doi: 10.1016/j.acuro.2012.02.005. Epub 2012 Apr 19.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J.
Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21.
Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features.
Mai KT, Collins JP, Veinot JP.
Appl Immunohistochem Mol Morphol. 2002 Sep;10(3):231-6. doi: 10.1097/00129039-200209000-00008.
An evaluation of durvalumab across the spectrum of urothelial carcinoma.
Oh EL, Redfern A, Hayne D.
Expert Rev Anticancer Ther. 2024 Nov;24(11):1101-1115. doi: 10.1080/14737140.2024.2405104. Epub 2024 Sep 20.
[Metastatic lymph node collision of a prostatic adenocarcinoma and an urothelial carcinoma and review of the literature].
Junca A, Frouin E, Irani J, Fromont G, Levillain P.
Ann Pathol. 2015 Dec;35(6):496-501. doi: 10.1016/j.annpat.2015.09.005. Epub 2015 Nov 17.
Nephrogenic Adenoma Intermixed With Urothelial Carcinoma.
Kryvenko ON, Wasco MJ, Williamson SR.
Arch Pathol Lab Med. 2022 May 1;147(5):552-558. doi: 10.5858/arpa.2021-0620-OA.
Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34betaE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
Iakymenko OA, Briski LM, Delma KS, Jorda M, Kryvenko ON.
Am J Surg Pathol. 2022 Apr 1;46(4):454-463. doi: 10.1097/PAS.0000000000001816.
